FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer
Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and tumor control at the 2022 ASCO Annual Meeting
ITIL-306 Phase 1 clinical study will enroll first patient with NSCLC and feature a regimen free of post-infusion IL-2
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.